INTerpath-014
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- NCT07513376 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on INTerpath-014 (intismeran and pembrolizumab coformulated with berahyaluronidase alfa in Non-small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on INTerpath-014 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Intismeran; Pembrolizumab coformulated with berahyaluronidase alfa; Placebo
- Arms
- Arm A: Intismeran + Pembrolizumab with Berahyaluronidase Alfa · Experimental
- Arm B: Intismeran · Experimental
- Arm C: Placebo · Placebo comparator
- Enrollment
- 876 (estimated)
- Primary outcomes
- Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C
- Sponsor
- Merck Sharp & Dohme LLC with ModernaTX, Inc.
- Start
- May 4, 2026
- Primary completion
- Aug 22, 2034 (estimated)
- Results posted
- No
- Registry record
- NCT07513376 · updated Oct 19, 2026